NASDAQ:NBRVNabriva Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nabriva Therapeutics PLC - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.75 0.00 (0.00 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.72Now: $0.75▼$0.7950-Day Range$0.50MA: $0.63▼$1.1452-Week Range$0.49Now: $0.75▼$2.77Volume11.26 million shsAverage Volume2.69 million shsMarket Capitalization$709.10 millionP/E RatioN/ADividend YieldN/ABeta2.43 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Nabriva Therapeutics plc, a biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. Its lead product candidate is lefamulin, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections, as well as Pediatric oral formulation. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Read More Beat the Market (BTM) Rank™ 4.2 Analyst's Opinion Consensus RatingNabriva Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.92, Nabriva Therapeutics has a potential upside of 422.6% from its current price of $0.75.Amount of Analyst CoverageNabriva Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesNabriva Therapeutics has received 371 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNabriva Therapeutics has received 302 “underperform” votes. (Add your “underperform” vote.)Community SentimentNabriva Therapeutics has received 55.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote “Outperform” if you believe NBRV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNabriva Therapeutics does not currently pay a dividend.Dividend GrowthNabriva Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nabriva Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.32% of the stock of Nabriva Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 2.43% of the stock of Nabriva Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nabriva Therapeutics are expected to grow in the coming year, from ($0.73) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nabriva Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nabriva Therapeutics is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNabriva Therapeutics has a P/B Ratio of 18.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBRV Previous Symbol CUSIPN/A CIK1641640 Webwww.nabriva.com Phone353-1649-2000Debt Debt-to-Equity Ratio0.37 Current Ratio3.19 Quick Ratio2.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.48 million Price / Sales74.80 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book18.74Profitability EPS (Most Recent Fiscal Year)($1.12) Net Income$-82,760,000.00 Net Margins-1,001.59% Return on Equity-238.67% Return on Assets-111.12%Miscellaneous Employees162 Outstanding Shares946,230,000Market Cap$709.10 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:NBRV Rates by TradingView Receive NBRV News and Ratings via Email Sign-up to receive the latest news and ratings for NBRV and its competitors with MarketBeat's FREE daily newsletter. Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions How has Nabriva Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Nabriva Therapeutics' stock was trading at $1.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NBRV stock has decreased by 38.1% and is now trading at $0.7494. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Nabriva Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Nabriva Therapeutics. When is Nabriva Therapeutics' next earnings date? Nabriva Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Nabriva Therapeutics. How were Nabriva Therapeutics' earnings last quarter? Nabriva Therapeutics PLC - (NASDAQ:NBRV) announced its earnings results on Monday, May, 11th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02. The biotechnology company had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.39 million. Nabriva Therapeutics had a negative net margin of 1,001.59% and a negative return on equity of 238.67%. View Nabriva Therapeutics' earnings history. What price target have analysts set for NBRV? 6 analysts have issued 12 month target prices for Nabriva Therapeutics' stock. Their forecasts range from $1.00 to $7.00. On average, they expect Nabriva Therapeutics' share price to reach $3.92 in the next year. This suggests a possible upside of 422.6% from the stock's current price. View analysts' price targets for Nabriva Therapeutics. Has Nabriva Therapeutics been receiving favorable news coverage? Headlines about NBRV stock have been trending somewhat positive recently, InfoTrie reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nabriva Therapeutics earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutNabriva Therapeutics. Who are some of Nabriva Therapeutics' key competitors? Some companies that are related to Nabriva Therapeutics include Arena Pharmaceuticals (ARNA), Uniqure (QURE), Axsome Therapeutics (AXSM), Alkermes (ALKS), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Intercept Pharmaceuticals (ICPT), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX), Prestige Consumer Healthcare (PBH), TG Therapeutics (TGTX) and Principia Biopharma (PRNB). View all competitors. What other stocks do shareholders of Nabriva Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include Agile Therapeutics (AGRX), SCYNEXIS (SCYX), AcelRx Pharmaceuticals (ACRX), Crispr Therapeutics (CRSP), Dynavax Technologies (DVAX), Melinta Therapeutics (MLNT), VBI Vaccines (VBIV), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Advanced Micro Devices (AMD). Who are Nabriva Therapeutics' key executives? Nabriva Therapeutics' management team includes the following people: Mr. Theodore R. Schroeder, CEO & Director (Age 65, Pay $707.62k)Mr. Steven P. Gelone, Pres & COO (Age 52, Pay $667.5k)Dr. Colin Broom, Director (Age 64, Pay $39.13k)Dr. Jennifer Schranz M.D., Chief Medical Officer (Age 55, Pay $620.85k)Mr. Gary L. Sender, Chief Financial Officer (Age 58) What is Nabriva Therapeutics' stock symbol? Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV." Who are Nabriva Therapeutics' major shareholders? Nabriva Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (0.18%), Rock Springs Capital Management LP (0.11%), Sabby Management LLC (0.04%), Morgan Stanley (0.04%), Wells Fargo & Company MN (0.01%) and Exane Derivatives (0.01%). Company insiders that own Nabriva Therapeutics stock include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Steven P Gelone and Theodore R Schroeder. View institutional ownership trends for Nabriva Therapeutics. Which institutional investors are selling Nabriva Therapeutics stock? NBRV stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Sabby Management LLC, and Morgan Stanley. Company insiders that have sold Nabriva Therapeutics company stock in the last year include Colin Md Broom, Gary Sender, and Steven P Gelone. View insider buying and selling activity for Nabriva Therapeutics. Which institutional investors are buying Nabriva Therapeutics stock? NBRV stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Exane Derivatives, and Wells Fargo & Company MN. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Charles A Rowland Jr, Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Jennifer Schranz, and Theodore R Schroeder. View insider buying and selling activity for Nabriva Therapeutics. How do I buy shares of Nabriva Therapeutics? Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Nabriva Therapeutics' stock price today? One share of NBRV stock can currently be purchased for approximately $0.75. How big of a company is Nabriva Therapeutics? Nabriva Therapeutics has a market capitalization of $709.10 million and generates $9.48 million in revenue each year. The biotechnology company earns $-82,760,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Nabriva Therapeutics employs 162 workers across the globe. What is Nabriva Therapeutics' official website? The official website for Nabriva Therapeutics is www.nabriva.com. How can I contact Nabriva Therapeutics? Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN 1 L2, 19406. The biotechnology company can be reached via phone at 353-1649-2000 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
